Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$2.83 USD
-0.16 (-5.35%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.82 -0.01 (-0.35%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TSHA 2.83 -0.16(-5.35%)
Will TSHA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Other News for TSHA
Fell Below 50 Day Moving Average appears for TSHA after 5.35% move
Is TSHA set to rally? Directional Movement Crossover Bullish shows up after rising 3.1%
What's Driving the Market Sentiment Around Taysha Gene Therapies?
TSHA forms 50 Day Moving Average Support on September 18
Is TSHA ready to move lower? 20 Day Moving Average Resistance shows up after tumbling 5.96%